In today’s recent session, 1.0 million shares of the Vanda Pharmaceuticals Inc (NASDAQ:VNDA) have been traded, and its beta is 0.66. Most recently the company’s share price was $4.87, and it changed around -$0.24 or -4.70% from the last close, which brings the market valuation of the company to $280.22M. VNDA at last check was trading at a discount to its 52-week high of $7.00, offering almost -43.74% off that amount. The share price’s 52-week low was $3.30, which indicates that the recent value has risen by an impressive 32.24% since then. We note from Vanda Pharmaceuticals Inc’s average daily trading volume that its 3-month average coming to 2.30 million.
Vanda Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 3.00. If we narrow it down even further, the data shows that 1 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended VNDA as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Vanda Pharmaceuticals Inc is expected to report earnings per share of $0.05 for the current quarter.
Vanda Pharmaceuticals Inc (NASDAQ:VNDA) trade information
Instantly VNDA has been showing red trend so far today with a performance of -4.70% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently up 15.40% year-to-date, but still up 19.95% over the last five days. On the other hand, Vanda Pharmaceuticals Inc (NASDAQ:VNDA) is 24.55% up in the 30-day period.
Vanda Pharmaceuticals Inc (VNDA) estimates and forecasts
Vanda Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 12.99 percent over the past six months and at a -250.00% annual growth rate that is well below the industry average of 13.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -58.30% in revenue this quarter, and will report a decrease of -33.30% in the next quarter. The year-over-year growth rate is expected to be 1.00%, up from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of $48.5 million in revenue for the current quarter. 1 analysts expect Vanda Pharmaceuticals Inc to make $47.5 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were -$ and $46.06 million respectively. Forecasts for the next quarter put sales growth at 3.10%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -37.98%.
